Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab

Archives of Dermatology

Volumn 147, Issue 10, 2011, Pages 1197-1202

  Gratton, David ^a   Szapary, Philippe ^c   Goyal, Kavitha ^d   Fakharzadeh, Steven ^c   Germain, Véronique ^b   Saltiel, Philippe ^b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTOCOR INC   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; LORAZEPAM; MAGNESIUM; METHOTREXATE; NITRIC OXIDE; PHENYTOIN; PIPERACILLIN; PROPOFOL; ROSUVASTATIN; STEROID; USTEKINUMAB;

ALCOHOL LIVER DISEASE; ALCOHOL WITHDRAWAL; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTICLE; BABINSKI REFLEX; BLOOD BRAIN BARRIER; BLOOD CELL COUNT; BLOOD PRESSURE; BODY MASS; BRAIN BLOOD VESSEL; BRAIN DISEASE; BRAIN EDEMA; BRAIN HYPOXIA; CELL ACTIVATION; CEREBROSPINAL FLUID ANALYSIS; CIGARETTE SMOKING; CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRINKING BEHAVIOR; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ELECTROLYTE BLOOD LEVEL; ENCEPHALITIS; FEVER; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION ENCEPHALOPATHY; IMAGE ANALYSIS; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIA; LEUKOCYTE COUNT; LOADING DRUG DOSE; LUMBAR PUNCTURE; MEDICAL HISTORY; MENINGITIS; MONOTHERAPY; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; PARANEOPLASTIC NEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS VULGARIS; REGULATORY MECHANISM; RESPIRATORY TRACT INTUBATION; SCORING SYSTEM; SEIZURE; SEPSIS; SEROLOGY; SEX RATIO; SINGLE DRUG DOSE; SOCIAL BEHAVIOR; SYSTEMIC CIRCULATION; THROMBOSIS; TREATMENT DURATION; TREMOR; UNCONSCIOUSNESS; VASOCONSTRICTION; VASODILATATION; VOMITING; WHITE MATTER;

AGED; ANTIBODIES, MONOCLONAL; FEMALE; HEADACHE; HUMANS; MAGNETIC RESONANCE IMAGING; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; SEIZURES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VOMITING;

EID: 80054734943     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.161     Document Type: Article

References (42)

1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500. (Pubitemid 26067737)
2. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J. 2005;35(2):83-90. (Pubitemid 40343439)
3. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29(6):1036-1042. (Pubitemid 351954863)
4. McKinney AM, Short J, Truwit CL, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007;189(4):904-912. (Pubitemid 47485623)
5. Marinella MA, Markert RJ. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J. 2009;39(12):826-834.
6. Pavlakis SG, Frank Y, Kalina P, Chandra M, Lu D. Occipital-parietal encephalopathy: a new name for an old syndrome. Pediatr Neurol. 1997;16(2):145-148. (Pubitemid 27137452)
7. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63(10):1475-1478. (Pubitemid 44547561)
8. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354(9):980-982.
9. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354(9):980-982.
10. Tolcher AW, Sweeney CJ, Papadopoulos K, et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res. 2011;17(2):363-371.
11. Haefner MD, Siciliano RD, Widmer LA, Vogel Wigger BM, Frick S. Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma. Onkologie. 2007;30(3):138-140. (Pubitemid 46384544)
12. Hosoi M, Yamamoto G, Imai Y, Kurokawa M. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma. Ann Hematol. 2010;89(2):207-208.
13. Kelly K, Kalachand R, Murphy P. Bortezomib-induced reversible posterior leucoencephalopathy syndrome. Br J Haematol. 2008;141(5):566. (Pubitemid 351667623)
14. Terwiel E, Hanrahan R, Lueck C, D'Rozario J. Reversible posterior encephalopathy syndrome associated with bortezomib. Intern Med J. 2010;40(1):69-71.
15. Kamimura H, Hirose S, Tazaki K, Suzuki Y, Satou M. Reversible posterior leukoencephalopathy syndrome with microscopic polyangiitis [in Japanese]. Nippon Naika Gakkai Zasshi. 2007;96(11):2532-2535.
16. Takashima S. Case of microscopic polyangiitis associated with reversible posterior leukoencephalopathy syndrome (RPLS) [in Japanese]. Nippon Naika Gakkai Zasshi. 2008;97(2):448-449.
17. Cosottini M, Lazzarotti G, Ceravolo R, Michelassi MC, Canapicchi R, Murri L. Cyclosporine-related posterior reversible encephalopathy syndrome (PRES) in non-transplant patient: a case report and literature review. Eur J Neurol. 2003;10(4):461-462.
18. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320-1327. (Pubitemid 47309666)
19. Renard D, Westhovens R, Vandenbussche E, Vandenberghe R. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol. 2004;251(2):226-228. (Pubitemid 38221640)
20. Marcon G, Giovagnoli AR, Mangiapane P, Erbetta A, Tagliavini F, Girotti F. Regression of chronic posterior leukoencephalopathy after stop of methotrexate treatment. Neurol Sci. 2009;30(5):375-378.
21. Akutsu N, Iwashita C, Maruyama M, et al. Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients. Transplant Proc. 2008;40(7):2416-2418.
22. Kastrup O, Diener HC. TNF-antagonist etanercept induced reversible posterior leukoencephalopathy syndrome. J Neurol. 2008;255(3):452-453.
23. Zamvar V, Puntis JW. Re: "Posterior reversible encephalopathy syndrome following infliximab infusion." J Pediatr Gastroenterol Nutr. 2010;50(3):353.
24. Zamvar V, Sugarman ID, Tawfik RF, Macmullen-Price J, Puntis JW. Posterior reversible encephalopathy syndrome following infliximab infusion. J Pediatr Gastroenterol Nutr. 2009;48(1):102-105.
25. Zito JA, Lee CC, Johnson S, Singer A, Vacirca J. Reversible posterior leukoencephalopathy syndrome after rituximab. Am J Emerg Med. 2010;28(4):537, e1-e2.
26. Kamar N, Kany M, Bories P, et al. Reversible posterior leukoencephalopathy syndrome in hepatitis C virus-positive long-term hemodialysis patients. Am J Kidney Dis. 2001;37(4):E29.
27. Ikeda M, Ito S, Hataya H, Honda M, Anbo K. Reversible posterior leukoencephalopathy in a patient with minimal-change nephrotic syndrome. Am J Kidney Dis. 2001;37(4):E30.
28. Kumar S, Rajam L. Posterior reversible encephalopathy syndrome (PRES/RPLS) during pulse steroid therapy in macrophage activation syndrome [published online ahead of print February 15, 2011]. Indian J Pediatr. doi:10.1007/s12098-011-0368-2.21318395.
29. Ishikura K, Ikeda M, Hamasaki Y, et al. Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome. Nephrol Dial Transplant. 2008;23(8):2531-2536.
30. Ohtonari T, Hashimoto M, Urasaki E, et al. Prolonged cerebral salt wasting following craniopharyngioma surgery and posterior reversible encephalopathy syndrome: a case report [in Japanese]. No To Shinkei. 2005;57(1):57-63. (Pubitemid 40410117)
31. Ozyurek H, Oguz G, Ozen S, et al. Reversible posterior leukoencephalopathy syndrome: report of three cases. Medscape Web site. http://www.medscape.com/viewarticle/522192. Accessed April 27, 2010.
32. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205-210. (Pubitemid 351240781)
33. Gümüş H, Per H, Kumandaş S, Yikilmaz A. Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature. Neurol Sci. 2010;31(2):125-131.
34. Bartlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet. 2008;371(9625):1639-1640. (Pubitemid 351671871)
35. Papp KA, Langley RG, Lebwohl M, et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675- 1684. (Pubitemid 351671884)
36. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29(6):1043-1049. (Pubitemid 351954864)
37. Brubaker LM, Smith JK, Lee YZ, Lin W, Castillo M. Hemodynamic and permeability changes in posterior reversible encephalopathy syndrome measured by dynamic susceptibility perfusion-weighted MR imaging. AJNR Am J Neuroradiol. 2005;26(4):825-830. (Pubitemid 43079775)
38. Di Lernia V. Progressive multifocal leukoencephalopathy and antipsoriatic drugs: assessing the risk of immunosuppressive treatments. Int J Dermatol. 2010;49(6):631-635.
39. Belmouaz S, Desport E, Leroy F, et al. Posterior reversible encephalopathy induced by intravenous immunoglobulin. Nephrol Dial Transplant. 2008;23(1):417-419. (Pubitemid 351767393)
40. Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003;122(1):128-134. (Pubitemid 36819347)
41. Avastin [package insert]. South San Francisco, CA: Genentech Inc; 2009.
42. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH; Ustekinumab MS Investigators. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7(9):796-804.